NCT06795399撤回2 期
A Phase 2, Randomized, Double-blind, Placebo-controlled, Proof of Concept Trial for OPC-131461 in Patients Hospitalized for Worsening Heart Failure With Laboratory Evidence of Incomplete Decongestion Following Urgent Decongestive Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 入组人数
- 264
- 主要终点
- Proportional Change From Baseline in Serum Concentration of NT-proBNP at Day 31
研究概览
简要总结
The primary objective of the study is to compare relative changes in blood N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels after 30 days of treatment in participants with worsening heart failure (WHF), who are treated with either OPC-131461 or placebo.
详细描述
Each participant in this trial is expected to participate in the following periods of the trial:
- Screening/qualification period: up to 48 hours (2 days)
- Double-blind treatment period: 30 days
- Safety follow-up period: 7 days
- Vital status follow-up period: 6 months
Eligible participants will be randomized to receive the study drug (1 of 2 dose levels [5 milligrams (mg) or 10 mg] of OPC-131461 tablets or placebo) in a 1:1:1 ratio.
Overall, the trial duration is expected to be approximately 210 days (7 months).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of HF ≥ 3 months prior to screening.
- •Admitted to the hospital with primary diagnosis of WHF and received treatment with intravenous (IV) diuretics.
- •Eligible participants will be randomized no earlier than 48 hours and up to 5 days after presentation to the hospital as long as they meet the following definition of stable status: Stable for at least 24 hours, defined by systolic blood pressure (SBP) ≥ 90 millimeters of mercury (mmHg) for preceding 24 hours, no increase in diuretic dose for 24 hours prior to randomization, did not receive IV inotropic or vasodilator (including nitrates) for 24 hours prior to randomization, and no oxygen therapy or mechanical ventilation in the 24 hours prior to randomization
- •Left ventricular ejection fraction (LVEF) assessed either during hospitalization for Index Event or within 12 months prior to randomization.
- •Has evidence of incomplete decongestion, indicated by NT-proBNP levels > 750 picograms per milliliter (pg/mL) (or > 1000 pg/mL if in atrial fibrillation). At hospital sites where NT proBNP test is unavailable at screening: B-type natriuretic peptide (BNP) > 375 pg/mL (or > 500 pg/mL if in atrial fibrillation).
排除标准
- •Primary cause of WHF (Index Event) due to valvular heart disease (defined as severe aortic or primary mitral regurgitation, moderate or severe aortic stenosis, any mitral stenosis requiring surgical repair, or active endocarditis), congenital heart disease, hypertrophic obstructive cardiomyopathy, pulmonary embolism, Type I myocardial infarction, infection, severe anemia, exacerbation of chronic obstructive pulmonary disease (COPD), or sustained ventricular tachycardia, or bradycardia with sustained ventricular rate < 45 beats/minute.
- •Duration of hospitalization for Index Event > 2 weeks at time of screening.
- •End-stage HF requiring at the time of screening left ventricular assist device (LVAD), intra-aortic balloon pump (IABP) or any similar mechanical support.
- •Cardiac surgery (coronary artery bypass grafting [CABG]), percutaneous coronary intervention (PCI), implantation of a cardiac device or cardiac mechanical support implantation within 30 days prior to randomization or planned during the study
- •Severely impaired renal function eGFR < 25 milliliters per minute per 1.73-meter square (mL/min/1.73m^2).
- •History of dialysis or kidney transplant.
- •History of cirrhosis or noncirrhotic portal hypertension.
- •Severe hyponatremia Sodium (Na) level < 125 mEq/L (milliequivalents per liter) or hypernatremia Na level > 145 mEq/L).
- •Systolic blood pressure < 90 mmHg at screening.
- •History of or current hepatitis or acquired immunodeficiency syndrome or carriers of hepatitis B surface antigen (HBsAg) and/or hepatitis C antibodies (anti-HCV), or human immunodeficiency virus (HIV) antibodies.
- •History of any significant drug allergy or known or suspected hypersensitivity to any component of the study drug.
- •Use of any investigational drug within 30 days prior to screening.
- •History of serious mental disorders that, in the opinion of the investigator, would exclude the participant from participating in this trial.
- •Note: Other protocol-specified inclusion and exclusion criteria may apply.
研究组 & 干预措施
Placebo
Placebo Comparator
Participants will receive OPC-131461 matched placebo, orally, once daily for 30 days.
干预措施: Placebo (Drug)
OPC-131461 10 mg
Experimental
Participants will receive OPC-131461 10 mg, orally, once daily for 30 days.
干预措施: OPC-131461 (Drug)
OPC-131461 5 mg
Experimental
Participants will receive OPC-131461 5 mg, orally, once daily for 30 days.
干预措施: OPC-131461 (Drug)
结局指标
主要结局
Proportional Change From Baseline in Serum Concentration of NT-proBNP at Day 31
时间窗: Baseline, Day 31
Proportional change from baseline in serum concentration of NT-proBNP is defined as the ratio of NT-proBNP at Day 31 over baseline.
次要结局
- Proportional Change From Baseline in Serum Concentration of NT-proBNP at Days 8 and 15(Baseline, Days 8 and 15)
- Change From Baseline in KCCQ-23 Total Symptom Score(Up to 31 days)
- Change From Baseline in KCCQ-23 Physical Limitations Score(Up to 31 days)
- Time to First Heart Failure (HF) Rehospitalization(From first dose of study drug up to end of treatment period (up to 30 days))
- Time to First Urgent HF Outpatient Visit(From first dose of study drug up to end of treatment period (up to 30 days))
- Time to Cardiovascular (CV) Death(From first dose of study drug up to end of treatment period (up to 30 days))
- Composite Endpoint Defined by the Win Ratio(From the first dose of the study drug up to end of treatment period (up to 30 days))
- Change From Baseline in Kansas City Cardiomyopathy Questionnaire - 23 items (KCCQ-23) Clinical Summary Score(Up to 31 days)
- Change From Baseline in Body Weight(Up to 37 days)
- Change From Baseline in EVEREST Congestion Score(Up to 37 days)
- Change From Baseline in Estimated Glomerular Filtration Rate (eGFR)(Up to 37 days)
- Number of Participants With Serum Electrolyte Abnormalities(Up to 37 days)
- Number of Participants With Major and Minor Bleeding Events(Up to 37 days)
- Number of Participants With Hypotension/Orthostatic Hypotension and Related Treatment-emergent Adverse Events (TEAEs) of Syncope and Presyncope(Up to 37 days)
研究者
相似试验
已完成
1 期
The Safety of a Hypolipidemic Agent in Healthy Normal VolunteersHealthyNCT01930240Cortria Corporation20
已完成
2 期
A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety DisorderSocial Anxiety DisorderNCT05193409Bionomics Limited151
终止
2 期
Study of ASN51 in Adults With Early Alzheimer's DiseaseAlzheimer DiseaseNCT06677203Asceneuron S.A.123
已完成
1 期
Metabolic Changes Induced by NMN in Healthy Subjects With Acute Binge DrinkBinge DrinkingNutritional SupplementationHepatic SteatosisLiver InjuryNCT05882214Zhejiang Chinese Medical University22
终止
2 期
Study of BIIB092 in Participants With Progressive Supranuclear PalsySupranuclear Palsy, ProgressiveNCT03068468Biogen490